The c-Met protein thought to be both a driver of cancer itself, as well as a resistance mechanism that tumours can develop to protect them from some widely-used NSCLC therapies, including EGFR ...

The c-Met protein is thought to be both a driver of cancer itself and a resistance mechanism that tumours can develop to protect them from some widely-used NSCLC therapies, including EGFR inhibitors.

Apollomics has sold the rights to its lead c-MET inhibitor in Asia ... and commercialize vebreltinib in combination with an EGFR inhibitor in Asia, excluding mainland China, Hong Kong and Macau.

The analyzed patients had EGFR-mutant NSCLC with high MET overexpression or amplification following treatment with first-line Tagrisso. The combo logged a 56% ORR by investigator assessment or 55% ...